Vertex completes rolling BLA submission for povetacicept after positive Phase 3 IgAN data
Vertex completed the rolling BLA submission for povetacicept in IgA nephropathy after positive Phase 3 RAINIER interim data. The company plans to use a Priority Review Voucher to accelerate FDA review.